Press release
Chronic Myelocytic Leukemia Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 25+ Companies are working to improve the Treatment of Space | Novartis Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, and Others
Chronic Myelocytic Leukemia Pipeline
Request a sample and discover the recent breakthroughs happening in the Chronic Myelocytic Leukemia Pipeline landscape @ Chronic Myelocytic Leukemia Pipeline Outlook- https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Chronic Myelocytic Leukemia Pipeline Report
• DelveInsight's Chronic Myelocytic Leukemia Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Chronic Myelocytic Leukemia treatment.
• The leading Chronic Myelocytic Leukemia Companies include Novarits Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc, Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, and others
• Promising Chronic Myelocytic Leukemia Pipeline Therapies include Bosutinib, imatinib, Nilotinib, Asciminib, Dasatinib Tablets, interferon-alpha (INF-a), cytarabine (ARA-C), and others
• The Chronic Myelocytic Leukemia companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myelocytic Leukemia (CML) R&D. The Chronic Myelocytic Leukemia therapies under development are focused on novel approaches to treat/improve Chronic Myelocytic Leukemia (CML).
• In February 2023, The FDA has given Dasynoc an ODD for the treatment of ALL and CML. The company anticipates receiving FDA approval by the time the product is launched in the United States in the second half of 2023.
• In March 2022, Inhibikase Therapeutics provided a reported update on IkT-001Pro, the Company's prodrug formulation of Imatinib mesylate, designed as a potentially safer, better-tolerated treatment for Imatinib-sensitive cancers such as stable-phase Chronic Myeloid Leukemia (CML). The Company is completing clinical batch manufacturing of pill formulated IkT-001Pro and conducting required stability studies and expects to submit the IND for IkT-001Pro in the second quarter of 2022. IkT-001Pro has received Orphan Drug Designation for stable-phase Chronic Myeloid Leukemia and will follow the development pathway for FDA Approval through the 505(b) (2) regulation.
Chronic Myelocytic Leukemia Overview
Chronic Myelocytic Leukemia (CML) (CMML) is a form of leukemia that is characterized by high numbers of white blood cells, called 'monocytes', in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukemia as part of its name, the World Health Organization (WHO) classifies CMML as a 'mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)'.
For further information, refer to the detailed Chronic Myelocytic Leukemia Drugs Launch, Chronic Myelocytic Leukemia Developmental Activities, and Chronic Myelocytic Leukemia News, click here for Chronic Myelocytic Leukemia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Chronic Myelocytic Leukemia Emerging Drugs Profile
• Sabatolimab: Novarits Oncology
Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. The drug is currently in phase III stage of development for the treatment of Chronic Myelocytic Leukemia (CML).
• Enasidenib: Servier
Enasidenib (AG 221) is a small molecule, oral inhibitor of isocitrate dehydrogenase 2 (IDH2), being developed by Servier. The drug is currently in phase I stage of development for the treatment of Chronic Myelocytic Leukemia (CML).
Chronic Myelocytic Leukemia Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Chronic Myelocytic Leukemia (CML). The companies which have their Chronic Myelocytic Leukemia (CML) drug candidates in the most advanced stage, i.e. phase III include, Novarits Oncology.
Find out more about the Chronic Myelocytic Leukemia Pipeline Segmentation, Therapeutics Assessment, and Chronic Myelocytic Leukemia Emerging Drugs @ Chronic Myelocytic Leukemia Treatment Landscape- https://www.delveinsight.com/sample-request/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Chronic Myelocytic Leukemia Pipeline Report
• Coverage- Global
• Chronic Myelocytic Leukemia Companies- Novarits Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc, Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, and others
• Chronic Myelocytic Leukemia Pipeline Therapies- Bosutinib, imatinib, Nilotinib, Asciminib, Dasatinib Tablets, interferon-alpha (INF-a), cytarabine (ARA-C), and others
• Chronic Myelocytic Leukemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for Chronic Myelocytic Leukemia Pipeline Companies and Therapies, click here @ Chronic Myelocytic Leukemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Chronic Myelocytic Leukemia (CML): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Myelocytic Leukemia (CML) - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Chronic Myelocytic Leukemia (CML) Collaboration Deals
9. Late Stage Products (Phase III)
10. Sabatolimab: Novartis
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Tefinostat: Chroma Therapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Enasidenib: Servier
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Chronic Myelocytic Leukemia (CML) Key Companies
20. Chronic Myelocytic Leukemia (CML) Key Products
21. Chronic Myelocytic Leukemia (CML)- Unmet Needs
22. Chronic Myelocytic Leukemia (CML)- Market Drivers and Barriers
23. Chronic Myelocytic Leukemia (CML)- Future Perspectives and Conclusion
24. Chronic Myelocytic Leukemia (CML) Analyst Views
25. Chronic Myelocytic Leukemia (CML) Key Companies
26. Appendix
Got Queries? Find out the related information on Chronic Myelocytic Leukemia Mergers and acquisitions, Chronic Myelocytic Leukemia Licensing Activities @ Chronic Myelocytic Leukemia Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Myelocytic Leukemia Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 25+ Companies are working to improve the Treatment of Space | Novartis Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, and Others here
News-ID: 3114502 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
